Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets

References

• Schuchat A, Houry D, Guy GP Jr. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6
   PubMed Web of Science ®Google Scholar
• Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 2017;167:293-301
   Google Scholar
• Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med 2016;374:1480-5
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6:107-12
   PubMed Web of Science ®Google Scholar
• Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag 2011;7:467-83
   PubMedGoogle Scholar
• Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012;15:ES67-92
   PubMed Web of Science ®Google Scholar
• Volkow ND, McLellan AT. Opioid abuse in chronic pain–misconceptions and mitigation strategies. N Engl J Med 2016;374:1253-63
   PubMed Web of Science ®Google Scholar
• Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704
   PubMed Web of Science ®Google Scholar
• Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. Int J Pharm 2016;510:57-72
   PubMedGoogle Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011;37:205-17
   PubMed Web of Science ®Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351-8
   PubMed Web of Science ®Google Scholar
• Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug Alcohol Depend 2017;176:89-95
   PubMed Web of Science ®Google Scholar
• Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend 2017;175:140-5
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Abuse-deterrent opioids—evaluation and labeling: guidance for industry. Silver Spring, MD: US Department of Health and Human Services; 2015. Available at: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf. [Last accessed 3 May 2017]
   Google Scholar
• Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011;8:29
   PubMed Web of Science ®Google Scholar
• ARYMO ER (morphine sulfate extended-release tablets). Full Prescribing Information, Egalet US Inc., Wayne, PA; 2017
   Google Scholar
• Cone EJ, Buchhalter AR, Lindhardt K, et al. The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. Am J Drug Alcohol Abuse 2017;43:291-8
   PubMed Web of Science ®Google Scholar
• Lindhardt K, Elhauge T, Skak N, et al. Injection and smoking resistance of EG-001, an abuse-deterrent ER morphine in clinical development. PAINWeek; September 2–6, 2014; Las Vegas, NV
   Google Scholar
• Smith MD, Webster LR, Lawler J, et al. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) versus extended-release morphine administered orally in nondependent recreational opioid users. Pain Med 2017;18:898-907
   PubMed Web of Science ®Google Scholar
• Webster LR, Smith MD, Lawler J, et al. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid users. Pain Med 2017;18:1695-705
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol Drug Saf 2017;26:56-62
   PubMed Web of Science ®Google Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18:255-63
   PubMed Web of Science ®Google Scholar
• Abreu ME, Bigelow GE, Fleisher L, et al. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001;154:76-84
   PubMed Web of Science ®Google Scholar
• de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berl) 1992;107:352-8
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, et al. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag 2009;5:203-12
   PubMedGoogle Scholar
• Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29:777-90
   PubMed Web of Science ®Google Scholar
• Webster LR, Pantaleon C, Shah MS, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine—morphine ARER. Pain Med 2016;18:1303-13
   Web of Science ®Google Scholar
• Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol 2014;54:468-77
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol 2017;57:500-12
   PubMed Web of Science ®Google Scholar
• Webster LR, Kopecky EA, Smith MD, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med 2016;17:1112-30
   PubMed Web of Science ®Google Scholar
• Harris SC, Cipriano A, Colucci SV, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med 2017;18:1278-91
   PubMed Web of Science ®Google Scholar
• Harris SC, Cipriano A, Colucci SV, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med 2016;17:820-31
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Ma Y, et al. Abuse potential with oral route of administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Pain Med 2017;18:61-77
   PubMed Web of Science ®Google Scholar
• Embeda (morphine sulfate and naltrexone hydrochloride capsule extended release). Full Prescribing Information. New York (NY): Pfizer Inc.; 2014
   Google Scholar
• Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride extended-release tablets). New York (NY): Pfizer Inc.; 2016
   Google Scholar
• Setnik B, Bass A, Bramson C, et al. Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to nondependent recreational opioid users. Pain Med 2017;18:1077-88
   PubMed Web of Science ®Google Scholar
• Setnik B, Bramson C, Bass A, et al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): a randomized, controlled abuse-potential study in nondependent recreational opioid users. J Clin Pharmacol 2015;55:1351-61
   PubMed Web of Science ®Google Scholar
• Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets). Stamford (CT): Purdue Pharma LP; 2014
   Google Scholar
• Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry 2015;72:424-30
   PubMed Web of Science ®Google Scholar
• Eaton TA, Comer SD, Revicki DA, et al. Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations. Qual Life Res 2012;21:975-81
   PubMed Web of Science ®Google Scholar
• White AG, LeCates J, Birnbaum HG, et al. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. J Opioid Manag 2015;11:199-210
   PubMedGoogle Scholar